Johnson & Johnson Archives - Vista Partners LLCVista Partners LLC

Pharma’s Evolving 2024 Acquisition Spree – $ABBV $EPRX $GILD $JNJ $LLY $MRK $NVS $VRTX

Based on reports from The Wall Street Journal, major pharmaceutical companies are shifting their focus to smaller acquisitions in 2024, with all 17 deals announced in the first half of the year valued at $5 billion or less, reflecting a changing regulatory landscape and a more selective approach to ...

Aug 21, 2024 View Article

Janssen, Johnson & Johnson’s Dutch Arm, To Shut Down Most Of Vaccine Division – $JNJ $DIA $IBB $LTRN

Reportedly, Janssen, the Dutch subsidiary of Johnson & Johnson (JNJ) and a key contributor to the development of the one-shot COVID-19 vaccine, has announced its intention to shut down nearly all operations within its vaccine division. The company's decision aligns with prior...

Aug 29, 2023 View Article

Johnson & Johnson Investor Conference Call: Q2 Review & Insights $JNJ $DIA $SPY $INVO

Reportedly, Johnson & Johnson (JNJ) is scheduled to host an investor conference call on Thursday, July 20th at 8:30 a.m. ET to review the second-quarter results. The conference call will be hosted by Joaquin Duato, Chairman of the Board and CEO, Executive VP and CFO , Joseph J. Wolk along with J...

Jun 08, 2023 View Article

J&J’s Experimental Pill Shows Promise Against Dengue Virus – $JNJ $DIA $INVO

As per reports, Johnson & Johnson (JNJ) has developed an experimental pill for dengue that has shown promising results in animal studies. According to data published the pill was effective against all four types of the dengue virus in mice and prevented infection from two types in monkeys. This ...

Mar 22, 2023 View Article

Johnson Adds Veteran Paula A. Johnson To Its Board – $JNJ $DIA $INVO

As per reports, Paula A. Johnson, MD, MPH, President of Wellesley College, has been appointed to its Board of Directors, Johnson & Johnson (JNJ) Dr. Johnson, is a veteran who brings decades of experience in the fields of public health, academic medicine, and higher education. Dr. Johnson current...

Feb 20, 2023 View Article

J&J Warns That Inflation & China’s Covid Outbreak May Hit 2023 Figures – $JNJ $DIA $INM

Reportedly, Dow 30 component Johnson & Johnson (JNJ) warned that the impact of high inflation and China's major COVID-19 outbreak may creep into 2023 impacting sales in the first half of the year at its medical devices segment. J&J forecast 2023 sales of $96.9 billion to $97.9 billion, putti...

Jan 31, 2023 View Article

J&J’s Spin-Off Kenvue Moves One Step Closer To NYSE Listing – $JNJ $DIA $KVUE $INM $ATOS

As per reports, Kenvue, Johnson & Johnson's (JNJ) newly formed consumer health unit files on the New York Stock Exchange to be listed as an independent company, more than a year after the consumer giant announced its plan to break up into two companies. The filing, for Kenvue will be listed unde...

Jan 20, 2023 View Article

Johnson & Johnson Acquires Abiomed – $JNJ $DIA $ABMD $ATOS $INVO

As per reports, Johnson & Johnson (JNJ) completed the acquisition of Abiomed, Inc. (ABMD) on December 22, 2022. Abiomed is now part of the company and will operate as an independent business within Johnson & Johnson’s MedTech segment. J&J’s made an upfront payment of $380 per share i...

Dec 29, 2022 View Article

Johnson’s CEO Joaquin Duato Succeeding Alex Gorsky As Chairman – $JNJ $DIA $ATOS

As per reports, Joaquin Duato, Johnson & Johnson (JNJ) CEO has been elected to lead as the Chairman succeeding Alex Gorsky, effective January next year. Gorsky to step down from his role as executive chairman. J&J veteran Duato replaced Gorsky as CEO earlier this year after leading a variet...

Dec 07, 2022 View Article

Janssen To Sue Amgen Over Marketing Plans For Similar Drug To Its $9.1B Stelara – $JNJ $AMGN $DIA $ATOS

As per reports, the Janssen unit of Johnson & Johnson (JNJ) has sued healthcare giant Amgen Inc as the latter plans to market drugs for ulcerative colitis and conditions similar to J&J's top-selling drug Stelara. Last year, Stelara generated $9.1 billion of the company's $52 billion in globa...

Dec 06, 2022 View Article

J&J Expected To Complete Heart Pump Maker Abiomed $16.B Acquisition By Q1/2023 – $JNJ $ABMD $DIA $ATOS $INVO

As per reports, Johnson & Johnson (JNJ) is set to acquire heart pump maker Abiomed (ABMD) in a deal valued at $16.6 billion to strengthen its cardiovascular devices business. The upfront payment of $380 per share represents a 50.7% premium to Abiomed's last closing price. The transaction is e...

Dec 01, 2022 View Article

Biotech Giant Amgen Completes The Acquisition Of ChemoCentryx – $AMGN $JNJ $DIA $ATOS

As per reports, Amgen (AMGN) has successfully acquired ChemoCentryx, Inc. (CCXI), for $52 per share in cash, representing aggregate merger consideration of approximately $3.7 billion. A biopharmaceutical company, ChemoCentryx, Inc is focused on orally-administered methods to treat cancer, inflammato...

Oct 26, 2022 View Article

Johnson & Johnson Earnings Move Higher On Cancer Drug Darzalex Demand – $JNJ $DIA $ATOS $INVO

Reportedly, Johnson & Johnson (JNJ) exceeded Wall Street estimates for quarterly revenue and profit on strong demand for its cancer drug Darzalex and Crohn's disease drug Stelara while projecting an easing of the hit from surging inflation. The company expects some impact of inflation to ease...

Dec 01, 2022 View Article

J&J’s Consumer Health Business Dubbed ‘Kenvue’ Ahead Of Spin Off – $JNJ $DIA $INVO

Reportedly, Johnson & Johnson (JNJ) has named its consumer business Kenvue moving ahead with its plans to spin off the unit. The unit has faced nearly 40,000 lawsuits alleging its baby powder and other talc products contained asbestos later linked to mesothelioma and ovarian cancer in women usin...

Sep 28, 2022 View Article

India’s Serum Institute & Aspen Enter Deal Utilizing Latter’s Idle COVID-19 Vaccine Unit – $JNJ $DIA

As per reports, Aspen Pharmacare has signed a deal with the Serum Institute of India to manufacture and sell four Aspen-branded vaccines for Africa, as it seeks to utilize its near-idle COVID-19 vaccine production lines in eastern South Africa. Aspen was under a contract with Johnson & Johnson ...

Sep 07, 2022 View Article

J&J To Discontinue Selling Its Talc-Based Baby Powder Globally – $JNJ $INVO $ATOS $DIA

As per reports, Johnson & Johnson (JNJ) announced that it plans to globally discontinue selling its talc-based baby powder in 2023, almost more than two years after it ended U.S. sales of the product amid thousands of consumer safety lawsuits. "As part of a worldwide portfolio assessment, we ha...

Aug 31, 2022 View Article

Low J&J Vaccine Demand Forces Production Halt At S.Africa’s Aspen Unit – $JNJ $DIA

Reportedly, South Africa's Aspen Pharmacare will stop making COVID-19 vaccines from the end of this month due to a lack of orders. Aspen currently produces vaccines for Johnson & Johnson. In March, it struck a deal to produce, price, and sell its own-brand version of the shot for African market...

Aug 30, 2022 View Article

Mathai Mammen Exits As Executive VP, Pharmaceuticals, R&D, Johnson & Johnson – $JNJ $DIA $IBB

As per reports, Mathai Mammen, M.D., Ph.D., has decided to leave his position as Executive Vice President, Pharmaceuticals, R&D, Johnson & Johnson (JNJ) and pursue other opportunities outside of the Company. Dr. Mammen joined Johnson & Johnson in 2017 as Global Head of Janssen R&D. W...

Aug 30, 2022 View Article

J&J Lowers Annual Profit Forecast As Dollar Strengthens – $JNJ $DIA

As per reports, Johnson & Johnson (JNJ) cut its full-year adjusted profit and sales forecast due to a hit from a stronger dollar, even though the company's pharmaceuticals unit boosted its second-quarter profit. The company's largest unit, pharmaceuticals have helped the company offset the blow...

Jul 22, 2022 View Article

Johnson & Johnson’s Executive VP, General Counsel Michael Ullmann To Retire – $JNJ $DIA

Reportedly, Johnson & Johnson (JNJ) announced the retirement of Michael Ullman, Executive VP, General Counsel at the end of this year with 33 years of leadership and service to the Company. Effective October 17, 2022, Ullmann will be succeeded by Elizabeth (Liz) Forminard having an exceptional e...

Jul 25, 2022 View Article

J&J To Soon Terminate Emergent Manufacturing Deal For COVID Vaccine Production – $JNJ $DIA

As per reports, Johnson & Johnson (JNJ) had formally informed Emergent BioSolutions Inc. of its decision to terminate the agreement with the contract manufacturer to make the COVID-19 vaccine for the drugmaker. Earlier, Emergent informed that J&J breached an agreement by failing to buy the m...

Jun 23, 2022 View Article

J&J Appoints Thibaut Mongon As CEO Of Its Soon To Be Spun Off Consumer Health Unit – $JNJ $DIA

Reportedly, Johnson & Johnson (JNJ) has appointed Thibaut Mongon as the chief executive officer of the consumer health division, the division which the pharmaceutical giant plans to spin off into a listed company by the end of next year. Mongon joined the company in 2000, and currently serves as...

May 12, 2022 View Article

US Health Regulators Limit The Use Of J&J’s COVID Vaccine Over Blood Clot Risks – $JNJ $DIA

Reportedly, the U.S. health regulator has issued notice to limit the use of the Johnson & Johnson (JNJ) COVID-19 vaccine for adults due to the high risk of a rare blood clotting syndrome. The Food and Drug Administration informed, that the J&J vaccine can be administered in cases where autho...

May 11, 2022 View Article

J&J Trims Annual Profit Forecast Due To Vaccine Performance – $JNJ DIA

Johnson & Johnson (JNJ) released quarterly earnings, refusing to provide a forecast for sales of its COVID-19 vaccine, as vaccine hesitancy in low-income countries and low demand in higher-income nations, lead to a surplus. J&J also cut both ends of its full-year profit forecast by 25 cents ...

Apr 20, 2022 View Article

J&J & Legend Biotech’s Multiple Myeloma CAR-T Therapy Receives Recommendation From European Medicines Agency – $JNJ $LEGN $DIA

Reportedly, the European Medicines Agency has recommended the use of CAR-T therapy to treat multiple myeloma by Johnson & Johnson (JNJ) and its partner Legend Biotech Corp. (LEGN) nearly a month after the treatment was cleared in the United States. The drug now needs the approval of the European...

Mar 25, 2022 View Article

J&J In Close Talks With S.Africa’s Aspen Over Vaccine Licensing Deal – $JNJ $DIA

Reportedly, Johnson & Johnson (JNJ) is close to a vaccine licensing deal with South African group Aspen Pharmacare, informed a senior executive at the company. In November, Aspen signed non-binding terms with subsidiaries of J&J, marking a step towards a licensing deal for Aspen to package a...

Feb 23, 2022 View Article

Darius Adamczyk, Chairman & CEO Honeywell, Appointed To Johnson & Johnson’s Board – $HON $JNJ $DIA

Reportedly, Johnson & Johnson (JNJ) announced the appointment of Darius Adamczyk, Chairman and Chief Executive Officer of Honeywell, to its Board of Directors. Currently, in his role as the Chairman and CEO of Honeywell, Darius Adamczyk has helped to bring solutions and technology to market that...

Feb 22, 2022 View Article

EU Countries Donate 2M Doses Of J&J COVID Vaccine To Nigeria As A Part Of COVAX Initiative

Reportedly, Nigeria has received 2 million doses of the Johnson & Johnson (JNJ) COVID-19 vaccine from Finland, Greece, and Slovenia. More EU donations are expected to arrive in the coming weeks, as part of a donation pledge by the European Union to African countries via the COVAX initiative laun...

Feb 10, 2022 View Article

J&J Reports Mixed Quarterly Report & 24.8B Sales – $JNJ $DIA

As per reports, Johnson & Johnson (JNJ) reported mixed quarter results with $28.4 billion in sales. Adjusted profit of $2.13 per share was reported a little higher than $2.12 expected and driven by high Covid vaccine sales. On a year-over-year basis, sales grew more than 10% and earnings advance...

Jan 27, 2022 View Article

J&J’s Booster Shot Effective In Preventing Hospitalization Caused By Omicron Variant In S. Africa -Study

Reportedly, a booster dose of Johnson & Johnson (JNJ) Inc's single-dose COVID-19 vaccine has proven to be 84% effective at preventing hospitalization in South African healthcare workers who became infected with the fast-spreading Omicron variant. The real-world study was based on a second dose o...

Jan 02, 2022 View Article

S. Africa’s Aspen Pharmacare Enters Agreement To Acquire License Of J&J’s COVID Vaccine

Reportedly, South Africa's Aspen Pharmacare has signed a non-binding agreement with subsidiary firms of U.S. company Johnson & Johnson (JNJ) for a licensing deal to package, market and sell the J&J’s COVID-19 vaccine in Africa. Currently, Aspen packages J&J's COVID-19 vaccine at its S...

Dec 01, 2021 View Article

Canada Allows Import Of J&J’s COVID-19 Vaccine From The Troubled Emergent Facility

As per reports, the Canadian health regulator has approved Johnson & Johnson (JNJ) to import its COVID-19 vaccine manufactured at Emergent BioSolutions Inc's plant in Baltimore, Maryland. The decision came after Health Canada completed an inspection of the facility, along with the European Medic...

Nov 30, 2021 View Article

J&J Targeting The Launch Of Multibillion-Dollar Drugs By 2025

As per reports, Johnson & Johnson (JNJ) is looking forward to filing for approval of 14 new drugs by 2025, projecting average peak sales of $4 billion a year for each. The global head of research for J&J's Janssen pharmaceutical unit, Mathai Mammen is reportedly confident about its top upcom...

Nov 19, 2021 View Article

J&J Dividing To Create 2 Public Co’s In Consumer & Healthcare

As per reports, Johnson & Johnson (JNJ) is to split its consumer products business from its pharmaceutical and medical device operations, creating two publicly traded companies. The move will separate its household/consumer products unit, maker of Band-Aid bandages, Aveeno and Neutrogena skincar...

Nov 14, 2021 View Article

J&J’s Chairman & CEO Alex Gorsky Added To Apple’s BOD

As per reports, Alex Gorsky, Chairman & CEO of Johnson & Johnson (JNJ) to join Apple’s (AAPL) board of directors. Gorsky joined Johnson & Johnson in 1988, accumulating a broad range of experience in sales, management, and marketing before becoming CEO in 2012. Gorky’s inclusion will ...

Nov 11, 2021 View Article

FDA Authorizes Batches Of J&J COVID-19 Vaccine From Emergent’s Baltimore Plant

As per reports, the U.S. Food and Drug Administration had authorized the use of two more batches of Johnson & Johnson (JNJ) one-dose COVID-19 vaccine manufactured at the problem-plagued Baltimore factory of Emergent BioSolutions Inc, based on a thorough review of facility records and quality tes...

Nov 10, 2021 View Article

J&J’s Q3 Profits Increased With Higher Sales In Consumer, Pharmaceutical & Medical Devices Units

Reportedly, Johnson & Johnson (JNJ) sold $502 million of its Covid-19 vaccine in the third quarter. The Pharma giant reported adjusted EPS of $2.60 per share versus $2.35 expected. Revenue stood at $23.34 billion versus $23.72 billion expected. The company maintained its Covid vaccine sales outl...

Oct 20, 2021 View Article

J&J Seeking FDA Approval For Authorization Of Its COVID-19 Vaccine Booster

As per reports, Johnson & Johnson has submitted data to the U.S. Food and Drug Administration for emergency use authorization of a booster shot of its COVID-19 vaccine in people aged 18 and above. The submission includes data from a late-stage study reporting a booster given 56 days after the fi...

Oct 06, 2021 View Article

Healthcare Giant J&J To Host Q3 Results Call On Oct 19th

Reportedly, Johnson & Johnson (JNJ) announced to host a conference call for investors at 8:30 a.m. on Tuesday, October 19th to review and analyze third-quarter results. The call will be hosted by Executive Vice President and Chief Financial Officer, Joseph J. Wolk. Teh. The senior leadership wil...

Sep 20, 2021 View Article

J&J’s Ebola Vaccine Demonstrated Promising Antibody Immune Responses In Adults & Children

As per reports, Johnson & Johnson (JNJ) Ebola vaccine regimen has demonstrated promising antibody immune responses in adults and children, as published in Lancet Infectious Diseases journal. J&J informed that the two-dose regimen was well-accepted and released antibody responses to the Zaire...

Sep 15, 2021 View Article

Johnson & Johnson’s HIV Vaccine Fails To Show Promising Results In Mid-Stage Africa Study

As per reports, Johnson & Johnson (JNJ) experimental vaccine failed to provide sufficient protection against HIV in sub-Saharan Africa to young women who accounted for a large number of infections last year. Results from the mid-stage study are the latest setback to efforts to develop a vaccine ...

Aug 31, 2021 View Article

Aspen Pharmacare To Supply First Batch Of J&J COVID-19 Vaccine To South Africa

Reportedly, South Africa's Aspen Pharmacare is to supply the first batch of Johnson & Johnson (JNJ) COVID-19 vaccines to the country from July 26. It is going to be the first set of vaccines to be manufactured in the country from active pharmaceutical ingredients (API), substances that are used ...

Jul 26, 2021 View Article

Johnson & Johnson Releases A Q2 Earnings Beat – Medical Device Unit Reported 62.7% Increase

Johnson & Johnson (JNJ) reported earnings exceeding analyst estimates reporting an adjusted EPS of $2.48 per share vs $2.27 expected. Revenue of $23.31 billion was reported, versus $22.21 billion expected. Johnson expects to sell $2.5 billion of its Covid-19 vaccine this year, even as its effect...

Jul 21, 2021 View Article

Johnson & Johnson’s Board Schedules Q3 Dividend

Reportedly, the board of Johnson & Johnson (JNJ) to pay a cash dividend of $1.06 per share on the company's common stock, for the third quarter of 2021 payable on September 7, 2021. The dividend is payable to shareholders of record at the close of business on August 24, 2021. Dow 30 c...

Jul 20, 2021 View Article

J&J Suspends/Recalls Aerosol Sunscreens Over Presence Of Carcinogen In Some Sprays

Reportedly, Johnson & Johnson (JNJ) is voluntarily suspending all lots of five Aveeno and Neutrogena brand aerosol sunscreen products from the market after internal testing identified low levels of a cancer-causing chemical, benzene in some samples. Benzene is known as a human carcinogen, a subs...

Jul 15, 2021 View Article

Johnson & Johnson’s Single-Shot COVID-19 Vaccine Receives Shell Life Extension Via FDA

As per reports, the U.S. Food and Drug Administration has extended the shelf life of the Johnson & Johnson (JNJ) single-shot COVID-19 vaccine from three months to four-and-a-half months, as millions of unused doses nationwide near expiry amid safety concerns and flagging demand for vaccinations....

Jun 14, 2021 View Article

Million Of J&J Vaccine Remain Unused In U.S, States Asked To Seek To Lengthen Shell Life

Reportedly, state governors to work with the U.S. Food and Drug Administration will be extending the shelf life of Johnson & Johnson's (JNJ) COVID-19 vaccine after White House orders, as millions of doses remain unused nationwide and are near to expiry. "I would encourage every governor who...

Jun 09, 2021 View Article

Mexico To Administer J&J’s COVID-19 US Supplied Vaccine To 18-40 Year Olds Along Mexico-U.S. Border

Reportedly, Mexico will seek to administer Johnson & Johnson's (JNJ) COVID-19 vaccine to 18 to 40-year-olds along the Mexico-U.S. border region with the aim of reopening the shared border by late June, informed Foreign Minister Marcelo Ebrard. After a conversation with U.S. Vice President Kamal...

Jun 07, 2021 View Article

Britain Authorizes Johnson & Johnson’s COVID-19 Vaccine For Use

Reportedly, Britain's medicine regulator has approved Johnson & Johnson's (JNJ) Janssen COVID-19 vaccine for use, making it the fourth COVID-19 vaccine to be approved in Britain. Britain had earlier approved vaccines made by Pfizer, AstraZeneca, and Moderna. The country reduced its order to 20 m...

May 29, 2021 View Article

GAVI Vaccine Alliance To Purchase 200M Doses Of Johnson & Johnson’s COVID-19 Vaccine

Reportedly, the GAVI Vaccine Alliance to buy 200 million doses of Johnson & Johnson's COVID-19 vaccine, as a major shortfall in the COVAX vaccine-sharing program is caused as India suspends vaccine exports. The country is fighting vaccine shortage and fails to fulfill its home demand as it fight...

May 26, 2021 View Article

Greece To Start Johnson & Johnson Coronavirus Vaccinations Next Month

Reportedly, Greece starts the rollout of the Johnson & Johnson (JNJ) COVID-19 vaccine on May 5 after Europe's drug regulator backed its use, informed health authorities. “We expect decisions by the CDC and FDA on Friday and then by our national committee on vaccinations in the following day...

Apr 22, 2021 View Article

Johnson & Johnson Reports Strong Quarter Earnings- Increases Quarterly Dividend By 5 Cents

As per reports, Johnson & Johnson (JNJ) released its first-quarter earnings this week, reporting adjusted earnings of $2.59 per share and revenue of $22.32 billion, beating estimates of $21.98 billion. The company reported $100 million in sales for its COVID-19 vaccine, which was put on hold by ...

Apr 21, 2021 View Article

FDA Halts Usage Of Johnson & Johnson COVID-19 Vaccine, As Blood-Clot Reports Appear

Reportedly, the Food and Drug Administration has halted the use of the Johnson & Johnson (JNJ) coronavirus vaccine, after reports of blood clots in six recipients were reported, pushing Johnson & Johnson's stock down. All six cases occurred in women between the ages of 18 and 48 with sympto...

Apr 13, 2021 View Article

Johnson’s Covid Vaccine Under Review By EU Regulator After Blood Clots Reports Surface

As per reports, Johnson & Johnson’s (JNJ) Covid-19 vaccine is under review by the European Union’s drug regulator after four critical cases of unusual clots accompanied by low blood platelets were reported after taking the immunization with the J&J shot. The regulator is now investigatin...

Apr 12, 2021 View Article

Johnson & Johnson Now In-Charge Of COVID-19 Vaccine Production At Baltimore Plant After 15 Million Doses Spoil

Reportedly, The U.S. Department of Health and Human Services has put Johnson & Johnson (JNJ) in charge of the Emergent BioSolutions facility in Baltimore that ruined 15 million doses of its COVID-19 vaccine. The incident has stopped British drugmaker AstraZeneca Plc from using the facility and w...

Apr 07, 2021 View Article

INVIMA Confirms Johnson & Johnson’s One Shot Covid-19 Vaccine Shot Receives Approval For Emergency Use In Columbia

Reportedly, Colombia has approved the emergency use of Johnson & Johnson's (JNJ) one-shot COVID-19 vaccine, informed the director of food and drug regulator INVIMA. The government has entered an agreement to buy 9 million doses of J&J's one-shot vaccine. "In its capacity as regulator, INV...

Mar 26, 2021 View Article

Johnson & Johnson COVID-19 Vaccine Approved For Use In Switzerland

Reportedly, Swiss drug regulator Swissmedic has approved Johnson & Johnson's (JNJ) COVID-19 vaccine for usage in the country, following the earlier two approved vaccines from Pfizer and BioNTech and from Moderna. Switzerland has so far not ordered J&J's one-shot vaccine, while deliveries hav...

Mar 22, 2021 View Article

Johnson & Johnson’s Multiple Sclerosis Treatment Drug Secures FDA Approval – Launching April 2021

Reportedly, FDA has approved Johnson & Johnson’s (JNJ) Ponvory, as a daily oral drug to treat relapsing forms of multiple sclerosis MS. The drug is expected to launch in early April 2021, entering a market currently dominated by big names like Novartis’ Kesimpta, Roche’s Ocrevus, and Gilen...

Mar 22, 2021 View Article

Johnson & Johnson COVID-19 Vaccine Gains Approval From Italy’s Medicines Agency For Usage

Reportedly, AIFA, Italy's medicines agency has approved the use of the single-dose COVID-19 vaccine produced by Johnson & Johnson following approval from the European drugs regulator last week. The J&J's vaccine approval marks fourth to be allowed for use in the European Union after vaccines...

Mar 16, 2021 View Article

FDA Approves Johnson & Johnson Single-Dose Covid-19 Vaccine Shot For Use In The U.S

As per reports, the Food & Drug Administration has given clearance to Johnson & Johnson (JNJ) Covid-19 one-shot vaccine giving the U.S its third vaccine to prevent the pandemic. Health officials have been waiting for a one-dose option instead of two to help fasten the vaccination drive, as t...

Mar 01, 2021 View Article

Johnson & Johnson Submits Covid-19 Vaccine Data To World Health Organization For Emergency Use Listing

As per reports, Johnson & Johnson (JNJ) has submitted data to the World Health Organization (WHO) for emergency use listing of its single-dose COVID-19 vaccine, allowing wider access. The healthcare giant informed that an emergency use listing is mandatory for supplying vaccines to the COVAX va...

Feb 23, 2021 View Article

Johnson & Johnson COVID-19 Vaccine Awaits FDA Authorization

Reportedly, Johnson & Johnson (JNJ) has submitted its single-shot coronavirus vaccine for emergency use with the Food and Drug Administration for authorization. If authorized, the company plans to supply the U.S. with 100 million doses in the first half of 2021, also it expects to begin shipment...

Feb 07, 2021 View Article

Highlights From Johnson & Johnson’s Q4 Earnings Release

Johnson & Johnson (JNJ) reported their Q4 earnings and revenue numbers which exceeded market estimates, reporting EPS of $1.86 per share versus $1.82 expected and revenue of $22.48 billion versus $21.67 billion expected. The company’s pharmaceutical unit, also working on a coronavirus vacci...

Jan 27, 2021 View Article

Johnson & Johnson Announces Q1 2021 Dividend Date

Reportedly, the Board of Johnson & Johnson (JNJ) has declared a cash dividend of $1.01 per share payable on March 9, 2021, to shareholders of common stock and of record at the close of business on February 23, 2021. Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare focused ...

Jan 08, 2021 View Article

All Johnson & Johnson Articles

Pharma’s Evolving 2024 Acquisition Spree – $ABBV $EPRX $GILD $JNJ $LLY $MRK $NVS $VRTX

Janssen, Johnson & Johnson’s Dutch Arm, To Shut Down Most Of Vaccine Division – $JNJ $DIA $IBB $LTRN

Johnson & Johnson Investor Conference Call: Q2 Review & Insights $JNJ $DIA $SPY $INVO

J&J’s Experimental Pill Shows Promise Against Dengue Virus – $JNJ $DIA $INVO

Johnson Adds Veteran Paula A. Johnson To Its Board – $JNJ $DIA $INVO

J&J Warns That Inflation & China’s Covid Outbreak May Hit 2023 Figures – $JNJ $DIA $INM

J&J’s Spin-Off Kenvue Moves One Step Closer To NYSE Listing – $JNJ $DIA $KVUE $INM $ATOS

Johnson & Johnson Acquires Abiomed – $JNJ $DIA $ABMD $ATOS $INVO

Johnson’s CEO Joaquin Duato Succeeding Alex Gorsky As Chairman – $JNJ $DIA $ATOS

Janssen To Sue Amgen Over Marketing Plans For Similar Drug To Its $9.1B Stelara – $JNJ $AMGN $DIA $ATOS

J&J Expected To Complete Heart Pump Maker Abiomed $16.B Acquisition By Q1/2023 – $JNJ $ABMD $DIA $ATOS $INVO

Biotech Giant Amgen Completes The Acquisition Of ChemoCentryx – $AMGN $JNJ $DIA $ATOS

Johnson & Johnson Earnings Move Higher On Cancer Drug Darzalex Demand – $JNJ $DIA $ATOS $INVO

J&J’s Consumer Health Business Dubbed ‘Kenvue’ Ahead Of Spin Off – $JNJ $DIA $INVO

India’s Serum Institute & Aspen Enter Deal Utilizing Latter’s Idle COVID-19 Vaccine Unit – $JNJ $DIA

J&J To Discontinue Selling Its Talc-Based Baby Powder Globally – $JNJ $INVO $ATOS $DIA

Low J&J Vaccine Demand Forces Production Halt At S.Africa’s Aspen Unit – $JNJ $DIA

Mathai Mammen Exits As Executive VP, Pharmaceuticals, R&D, Johnson & Johnson – $JNJ $DIA $IBB

J&J Lowers Annual Profit Forecast As Dollar Strengthens – $JNJ $DIA

Johnson & Johnson’s Executive VP, General Counsel Michael Ullmann To Retire – $JNJ $DIA

J&J To Soon Terminate Emergent Manufacturing Deal For COVID Vaccine Production – $JNJ $DIA

J&J Appoints Thibaut Mongon As CEO Of Its Soon To Be Spun Off Consumer Health Unit – $JNJ $DIA

US Health Regulators Limit The Use Of J&J’s COVID Vaccine Over Blood Clot Risks – $JNJ $DIA

J&J Trims Annual Profit Forecast Due To Vaccine Performance – $JNJ DIA

J&J & Legend Biotech’s Multiple Myeloma CAR-T Therapy Receives Recommendation From European Medicines Agency – $JNJ $LEGN $DIA

J&J In Close Talks With S.Africa’s Aspen Over Vaccine Licensing Deal – $JNJ $DIA

Darius Adamczyk, Chairman & CEO Honeywell, Appointed To Johnson & Johnson’s Board – $HON $JNJ $DIA

EU Countries Donate 2M Doses Of J&J COVID Vaccine To Nigeria As A Part Of COVAX Initiative

J&J Reports Mixed Quarterly Report & 24.8B Sales – $JNJ $DIA

J&J’s Booster Shot Effective In Preventing Hospitalization Caused By Omicron Variant In S. Africa -Study

S. Africa’s Aspen Pharmacare Enters Agreement To Acquire License Of J&J’s COVID Vaccine

Canada Allows Import Of J&J’s COVID-19 Vaccine From The Troubled Emergent Facility

J&J Targeting The Launch Of Multibillion-Dollar Drugs By 2025

J&J Dividing To Create 2 Public Co’s In Consumer & Healthcare

J&J’s Chairman & CEO Alex Gorsky Added To Apple’s BOD

FDA Authorizes Batches Of J&J COVID-19 Vaccine From Emergent’s Baltimore Plant

J&J’s Q3 Profits Increased With Higher Sales In Consumer, Pharmaceutical & Medical Devices Units

J&J Seeking FDA Approval For Authorization Of Its COVID-19 Vaccine Booster

Healthcare Giant J&J To Host Q3 Results Call On Oct 19th

J&J’s Ebola Vaccine Demonstrated Promising Antibody Immune Responses In Adults & Children

Johnson & Johnson’s HIV Vaccine Fails To Show Promising Results In Mid-Stage Africa Study

Aspen Pharmacare To Supply First Batch Of J&J COVID-19 Vaccine To South Africa

Johnson & Johnson Releases A Q2 Earnings Beat – Medical Device Unit Reported 62.7% Increase

Johnson & Johnson’s Board Schedules Q3 Dividend

J&J Suspends/Recalls Aerosol Sunscreens Over Presence Of Carcinogen In Some Sprays

Johnson & Johnson’s Single-Shot COVID-19 Vaccine Receives Shell Life Extension Via FDA

Million Of J&J Vaccine Remain Unused In U.S, States Asked To Seek To Lengthen Shell Life

Mexico To Administer J&J’s COVID-19 US Supplied Vaccine To 18-40 Year Olds Along Mexico-U.S. Border

Britain Authorizes Johnson & Johnson’s COVID-19 Vaccine For Use

GAVI Vaccine Alliance To Purchase 200M Doses Of Johnson & Johnson’s COVID-19 Vaccine

Greece To Start Johnson & Johnson Coronavirus Vaccinations Next Month

Johnson & Johnson Reports Strong Quarter Earnings- Increases Quarterly Dividend By 5 Cents

FDA Halts Usage Of Johnson & Johnson COVID-19 Vaccine, As Blood-Clot Reports Appear

Johnson’s Covid Vaccine Under Review By EU Regulator After Blood Clots Reports Surface

Johnson & Johnson Now In-Charge Of COVID-19 Vaccine Production At Baltimore Plant After 15 Million Doses Spoil

INVIMA Confirms Johnson & Johnson’s One Shot Covid-19 Vaccine Shot Receives Approval For Emergency Use In Columbia

Johnson & Johnson COVID-19 Vaccine Approved For Use In Switzerland

Johnson & Johnson’s Multiple Sclerosis Treatment Drug Secures FDA Approval – Launching April 2021

Johnson & Johnson COVID-19 Vaccine Gains Approval From Italy’s Medicines Agency For Usage

FDA Approves Johnson & Johnson Single-Dose Covid-19 Vaccine Shot For Use In The U.S

Johnson & Johnson Submits Covid-19 Vaccine Data To World Health Organization For Emergency Use Listing

Johnson & Johnson COVID-19 Vaccine Awaits FDA Authorization

Highlights From Johnson & Johnson’s Q4 Earnings Release

Johnson & Johnson Announces Q1 2021 Dividend Date

Stay Informed. Stay Competitive.

Vista Partners offers an exclusive newsletter and content with daily, weekly, monthly and quarterly investing ideas, strategies, and marketing insights.

Recent Posts

VP Watchlist

Trending Posts

Connect with us